INTERNATIONAL PATENT: ALEXION PHARMACEUTICALS, INC. FILES APPLICATION FOR "RISK EVALUATION AND MANAGEMENT STRATEGY INVOLVING PATIENT FOLLOW-UPS RELATING TO THE USE OR DISCONTINUATION OF A COMPLEMENT INHIBITOR"

GENEVA, Oct. 1 -- ALEXION PHARMACEUTICALS, INC. (121 Seaport BoulevardBoston, MA 02210) filed a patent application (PCT/US2025/020377) for "RISK EVALUATION AND MANAGEMENT STRATEGY INVOLVING PATIENT FOLLOW-UPS RELATING TO THE USE OR DISCONTINUATION OF A COMPLEMENT INHIBITOR" on Mar 18, 2025. With publication no. WO/2025/199107, the details related to the patent application was published on Sep 25, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): FRISE, Sarah Anne (c/o Alexion Pharmaceuticals, Inc.121 Seaport BoulevardBoston, MA 02210)

Abstract: A method of treating a patient with a complement...